
The phase II prospective study assessed the efficacy and safety of whole brain radiotherapy (WBRT) combined with anlotinib in patients with advanced non-small cell lung cancer (NSCLC) and multiple brain metastases (BMs). Twenty-eight patients were treated with anlotinib (8–12 mg) during a 21-day cycle alongside WBRT (30 Gy/12 F) and maintenance anlotinib until disease progression. Key outcomes included intracranial progression-free survival (iPFS), intracranial objective response rate (iORR), and overall survival (OS). Results revealed a median iPFS of 11.1 months and median OS of 13.4 months, with a 71.4% iORR. Common adverse events included hypertension (71.4%), fatigue (64.3%), and anorexia (46.4%). Findings suggest that anlotinib combined with WBRT offers effective, well-tolerated treatment for NSCLC with BMs.
Like
Save
Share